Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial

Bang, Yung Jue; Kim, Young Woo; Yang, Han Kwang; Chung, Hyun Cheol; Park, Young Kyu; Lee, Kyung Hee; Lee, Moon Hyoung; Kim, Yong Ho; Noh, Sang Ik; Cho, Jae Yong; Mok, Young Jae; Kim, Yeul Hong; Ji, Jiafu; Yeh, Ta Sen; Button, Peter; Sirzén, Florin; Noh, Sung Hoon

doi:10.1016/s0140-6736(11)61873-4

Cited by 1,477 publications

(1,235 citation statements)

References 24 publications

Supporting

Mentioning

1,136

Contrasting

Unclassified

Order By: Relevance

“…Although the relapse patterns in the three groups also failed to reach statistical difference, it was noted that the rate of distant metastasis in groups II or III (30% vs.20%) was lower than in group I (56.6%). The toxic effects of adjuvant chemotherapy have been reported in previous studies, and include leukopenia, anemia, thrombocytopenia, nausea, vomiting, and other rare toxic effects (Saletti et al, 2007;Di Costanzo et al, 2008;Bang et al, 2012). In our study, the toxic events of grade 3 or 4 were more frequent in group III than in the other groups.…”

Section: Discussionsupporting

confidence: 68%

“…Adjuvant chemotherapy has recently become one of the standard treatments after resection of gastric cancers in some Asian countries (Sakuramoto et al, 2007;Bang et al, 2012). Meta-analyses indicated that patients with resectable gastric cancer could actually benefit from adjuvant chemotherapy (Oba, 2009;Paoletti et al, 2010).…”

Section: Discussionmentioning

confidence: 99%

“…Kang et al (2011) reported that 6 cycles of adjuvant S-1 plus cisplatin was feasible for patients with stomach cancer undergoing surgical resection. Bang et al (2012) showed that 8 cycles of chemotherapy after D2 gastrectomy increased 3 year disease-free survival rates and lowered the risk of recurrence. Five-year outcomes of a randomized phase III trial by Sasako et al (2011) showed that patients with gastric cancer undergoing D2 gastrectomy could benefit from 8 cycles of postoperative adjuvant chemotherapy with S-1.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Impact of Adjuvant Chemotherapy Cycles on Prognosis of Resectable Stomach Cancer: A Retrospective Analysis

Zhang

Zhang²,

Bai³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Aims: The aim of this study was to investigate the effects of adjuvant chemotherapy cycles on the prognosis of patients with post-operative stomach cancer through retrospective analysis. Methods: A total of 128 patients with gastric cancer who underwent gastrectomy, followed by adjuvant chemotherapy consisting of epirubicin, cisplatin or oxaliplatin, leucovorin, and 5-fluorouracil, according to a defined schedule, were divided into three groups according to the number of chemotherapy cycles: Group I (<6 cycles); Group II (6 cycles

show abstract

Section: Discussionsupporting

confidence: 68%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Impact of Adjuvant Chemotherapy Cycles on Prognosis of Resectable Stomach Cancer: A Retrospective Analysis

Zhang

Zhang²,

Bai³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…These results suggest that preoperative high GAR (> 0.80) would be a good indication for the new postoperative chemotherapies such as S‐1 plus oxaliplatin and capecitabine plus oxaliplatin in stage II and III of GC patients. Several previous studies have reported that S‐1 plus oxaliplatin and capecitabine plus oxaliplatin were applicable and safe as a new postoperative chemotherapy for stage II and III of GC patients 40, 41, 42. As a bias of this study, all stage II and III of GC patients did not receive postoperative chemotherapy using S‐1.…”

Section: Discussionmentioning

confidence: 79%

Preoperative globulin‐to‐albumin ratio predicts outcome after curative resection in patients with gastric cancer

Shioiri

Ishizuka

Shibuya

et al. 2018

Annals of Gastroent Surgery

View full text Add to dashboard Cite

AimThe globulin‐to‐albumin ratio (GAR) is useful for prognostication of patients with various cancers. However, the significance of GAR in gastric cancer (GC) remains unclear. Our purpose was to investigate the relationship between the GAR and outcome after curative resection in GC patients.MethodsThree‐hundred and seventy‐six patients who had undergone curative resection for GC were retrospectively reviewed. Univariate and multivariate analyses using the Cox proportional hazard model were performed to detect clinical characteristics that correlated with overall survival (OS), and their cut‐off values were identified using receiver operating characteristic (ROC) curve analyses. Kaplan–Meier analysis and log‐rank test were used for comparison of OS and relapse‐free survival (RFS).ResultsMultivariate analysis using 17 clinical characteristics selected by univariate analyses revealed that GAR (>0.80/≤0.80) was significantly associated with OS (hazard ratio [HR], 2.305; 95% CI, 1.122‐4.735; P = 0.023), as well as lymph node metastasis (presence/absence) (HR, 2.417; 95% CI, 1.077‐5.426; P = 0.032), neutrophil‐to‐lymphocyte ratio (>2.7/≤2.7) (HR, 2.368; 95% CI, 1.138‐4.930; P = 0.002), and serosal invasion (presence/absence) (HR, 3.443; 95% CI, 1.048‐11.31; P = 0.042). Kaplan–Meier analysis and log‐rank test demonstrated that the OS and RFS of patients with a high GAR (>0.80) were significantly poorer than those with low GAR (≤0.80).ConclusionsThe GAR is a useful predictor of postoperative outcome among GC patients undergoing curative resection.

show abstract

“…GC is considered as a multifactorial disease due to numerous inherited and environmental factors, including genetic background, infectious agents and dietary habits (3). Surgery remains the only curative therapy for GC treatment, and perioperative and adjuvant chemotherapy can improve the outcome (4,5). However, no clear superiority of one strategy over others has been observed, and serious side effects and dose-limiting toxicities of chemotherapy treatments are common (6).…”

Section: Introductionmentioning

confidence: 99%

Trametes robiniophila may induce apoptosis and inhibit MMPs expression in the human gastric carcinoma cell line MKN-45

Pan

et al. 2016

Oncology Letters

View full text Add to dashboard Cite

Abstract. Gastric carcinoma (GC) is one of the most common malignant tumors and is mainly treated by invasive surgeries. The present study aimed to investigate the treatment potential of Trametes robiniophila on GC using the human GC cell line MKN-45. Cells were incubated with Trametes robiniophila at a concentration of 0, 5 and 10 mg/ml for 24 h. The apoptosis of the cell line was examined with acridine orange/ethidium bromide staining and flow cytometry. The expression of B-cell lymphoma (Bcl)-2, Fas, caspase-3, matrix metalloproteinase (MMP)-2 and MMP-9 was analyzed using reverse transcription-polymerase chain reaction and western blotting. With increasing drug concentrations, the proportion of apoptotic and necrotic cells increased. For a certain concentration, the apoptotic ratio also increased with increasing response times. Compared with the control group, the Bcl-2, MMP-2 and MMP-9 expression levels in the MKN-45 cell line decreased, while the expression levels of Fas and caspase-3 increased (P<0.05), and the expression patterns were strengthened with increasing drug concentrations. The present study revealed that Trametes robiniophila had treatment potential on GC, and it may act on gastric cells through apoptotic induction and MMPs expression inhibition. Based on the present results, Trametes robiniophila may be considered as an alternative approach for noninvasive therapy of GC. However, future studies should be performed to clarify this further.

show abstract

Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial

Cited by 1,477 publications

References 24 publications

Impact of Adjuvant Chemotherapy Cycles on Prognosis of Resectable Stomach Cancer: A Retrospective Analysis

Impact of Adjuvant Chemotherapy Cycles on Prognosis of Resectable Stomach Cancer: A Retrospective Analysis

Preoperative globulin‐to‐albumin ratio predicts outcome after curative resection in patients with gastric cancer

Trametes robiniophila may induce apoptosis and inhibit MMPs expression in the human gastric carcinoma cell line MKN-45

Contact Info

Product

Resources

About